Toll-like receptor 7-driven lupus autoimmunity induces hypertension and vascular alterations in mice
- PMID: 32004206
- DOI: 10.1097/HJH.0000000000002368
Toll-like receptor 7-driven lupus autoimmunity induces hypertension and vascular alterations in mice
Abstract
Objective: To investigate whether toll-like receptor 7 (TLR7) activation induces an increase in blood pressure and vascular damage in wild-type mice treated with the TLR7 agonist imiquimod (IMQ).
Methods: Female BALB/c mice (7-9 week old) were randomly assigned to two experimental groups: an untreated control group and a group treated topically with IMQ (IMQ-treated) for 4 or 8 weeks. A group of IMQ-treated mice that take a combination of the antioxidants tempol and apocynin, and another treated IL-17-neutralizing antibody were also performed.
Results: TLR7 activation gradually increased blood pressure, associated with elevated plasma levels of anti-dsDNA autoantibodies, splenomegaly, hepatomegaly, and severe expansion of splenic immune cells with an imbalance between proinflammatory T cells and regulatory T cells. TLR7 activation induced a marked vascular remodeling in mesenteric arteries characterized by an increased media--lumen ratio (≈40%), and an impaired endothelium-dependent vasorelaxation in aortas from wild-type mice after 8 weeks of treatment. In addition, an increased ROS production, as a result of the upregulation of NADPH oxidase subunits, and an enhanced vascular inflammation were found in aortas from IMQ-treated mice. These functional and structural vascular alterations induced by IMQ were improved by antioxidant treatment. Anti-IL-17 treatment reduced blood pressure and improved endothelial dysfunction in IMQ-treated mice.
Conclusion: Our results demonstrate that TLR7 activation induces the development of hypertension and vascular damage in BALB/c mice, and further underscore the increased vascular inflammation and oxidative stress, mediated in part by IL-17, as key factors contributing to cardiovascular complications in this TLR7-driven lupus autoimmunity model.
Comment in
-
Hypertension and vascular alterations in lupus autoimmunity.J Hypertens. 2020 Jul;38(7):1257-1258. doi: 10.1097/HJH.0000000000002405. J Hypertens. 2020. PMID: 32502094 No abstract available.
Similar articles
-
Probiotics Prevent Hypertension in a Murine Model of Systemic Lupus Erythematosus Induced by Toll-Like Receptor 7 Activation.Nutrients. 2021 Jul 31;13(8):2669. doi: 10.3390/nu13082669. Nutrients. 2021. PMID: 34444829 Free PMC article.
-
Gut Microbiota Has a Crucial Role in the Development of Hypertension and Vascular Dysfunction in Toll-like Receptor 7-Driven Lupus Autoimmunity.Antioxidants (Basel). 2021 Sep 7;10(9):1426. doi: 10.3390/antiox10091426. Antioxidants (Basel). 2021. PMID: 34573058 Free PMC article.
-
Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.J Dermatol Sci. 2016 Oct;84(1):59-70. doi: 10.1016/j.jdermsci.2016.07.007. Epub 2016 Jul 12. J Dermatol Sci. 2016. PMID: 27449383
-
Impact of apocynin on vascular disease in hypertension.Vascul Pharmacol. 2016 Dec;87:1-5. doi: 10.1016/j.vph.2016.08.006. Epub 2016 Aug 26. Vascul Pharmacol. 2016. PMID: 27569106 Review.
-
Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation.Semin Immunopathol. 2019 Mar;41(2):153-164. doi: 10.1007/s00281-018-0712-y. Epub 2018 Oct 1. Semin Immunopathol. 2019. PMID: 30276444 Review.
Cited by
-
Metabolic Modulators in Cardiovascular Complications of Systemic Lupus Erythematosus.Biomedicines. 2023 Nov 25;11(12):3142. doi: 10.3390/biomedicines11123142. Biomedicines. 2023. PMID: 38137363 Free PMC article. Review.
-
Probiotics and Prebiotics in Cardiovascular Diseases.Nutrients. 2023 Aug 23;15(17):3686. doi: 10.3390/nu15173686. Nutrients. 2023. PMID: 37686718 Free PMC article.
-
TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension.Eur Respir J. 2023 Jul 20;62(1):2300204. doi: 10.1183/13993003.00204-2023. Print 2023 Jul. Eur Respir J. 2023. PMID: 37290790 Free PMC article.
-
Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor.Antioxidants (Basel). 2023 Feb 10;12(2):440. doi: 10.3390/antiox12020440. Antioxidants (Basel). 2023. PMID: 36830003 Free PMC article.
-
Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.Front Physiol. 2022 Jul 6;13:930353. doi: 10.3389/fphys.2022.930353. eCollection 2022. Front Physiol. 2022. PMID: 35874527 Free PMC article.
References
-
- Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012; 18:871–882.
-
- Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun 2017; 82:1–12.
-
- Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol 2018; 14:1043–1053.
-
- Sella EM, Sato EI, Barbieri A. Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum 2003; 48:3168–3175.
-
- June RR, Scalzi LV. Peripheral vascular disease in systemic lupus patients. J Clin Rheumatol 2013; 19:367–372.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
